Ramesh K. Ramanathan

Ironwood Pharmaceuticals (United States) — United States

Medicine · Health Sciences

71h-index30.9kcitations469works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(110), Colorectal Cancer Treatments and Studies(96), Cancer Treatment and Pharmacology(73), Cancer Genomics and Diagnostics(63), Cancer therapeutics and mechanisms(43)

Publications469 total

A Brief Report on Outcomes of Metastatic Non-Small Cell Lung Cancer: A Retrospective Observational Study in a Community Practice Setting
Cureus·2025Open Access
Abstract P2-08-05: Pembrolizumab (P) added to Neoadjuvant Chemotherapy (NACT) for Triple Negative Breast Cancer (TNBC) in a community practice setting: Real World Evidence (RWE) for the effectiveness of the KN -522 regimen
Clinical Cancer Research·2025
Analysis of lipogenic and metabolic subtypes and survival outcome in patients with pancreatic adenocarcinoma.
Journal of Clinical Oncology·2025
Genomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer
Scientific Reports·2024· 6 citedOpen Access
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Journal of Clinical Oncology·2023· 117 cited
A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.
Journal of Clinical Oncology·2023· 2 cited
Supplementary Methods from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
2023Open Access
Figure S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 7 from Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Table S3 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Table S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
2023Open Access
Figure S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
2023Open Access
Table S4 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Figure S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Methods from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
2023Open Access
Supplementary Figure S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
2023Open Access
Supplementary Figure S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
2023Open Access
Data from Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023Open Access
page 1 of 24Next →

Frequent Co-authors

Daniel D. Von Hoff(8), Richard M. Goldberg(8), Daniel J. Sargent(7), Roscoe F. Morton(6), Charles S. Fuchs(6), Stephen K. Williamson(6), B. Findlay(6), Daniel A. Laheru(5), Steven R. Alberts(5), Mitesh J. Borad(5), Glen J. Weiss(5), Merrill J. Egorin(5), E. Gabriela Chiorean(4), Jeffrey R. Infante(4), Henry C. Pitot(4), Philip A. Philip(4), Lowell L. Hart(4), Jasgit C. Sachdev(4), Eric Van Cutsem(3), Christopher H. Crane(3)